Program
dalmelitinib
Also written as “HS-10241” and “HS-10241+ Almonertinib”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms · Carcinoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 62 open or running | phase 3since Oct 24, 2023 | Nov 11, 2016 | none ahead |
| Jiangsu HengRui Medicine | 10 open or running | phase 1since Apr 29, 2016 | Apr 29, 2016 | none ahead |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
Dalmelitinib (HS-10241)
, phase 4, as of Aug 26, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 29, 2016First study: phase 1 study in NeoplasmsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT02759640 · 7 enrolled · Australia
- Nov 11, 2016Hansoh Pharmaceutical Group's first study: phase 1 study in CarcinomaNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT02977364 · 50 enrolled · China
- Jul 18, 2017Phase 1 study in Advanced CancerHansoh Pharmaceutical Group · NCT03243643 · 80 enrolled · China
- Apr 27, 2020Phase 1 study in Solid TumorHansoh Pharmaceutical Group · NCT04477057 · 30 enrolled · China
- Jun 14, 2022Phase 1 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT05430386 · 174 enrolled · China
- Oct 24, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT06110663 · 314 planned
- Dec 23, 2024Phase 1 study in Advanced Non-small Cell Lung CancerHansoh Pharmaceutical Group · NCT06823245 · 32 planned
TargetBeta
“An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, HS-10241 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal…”NCIt, read by Claude
“An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), ”NCIt, by rule
Other programs on MET
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Crizotinibrule | Pfizer | phase 4 | 31 |
| telisotuzumab adizutecan | AbbVie | phase 3 | 18 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| vebreltinibrule | beijing-pearl-biotechnology-limited-liability-company | phase 3 | 9 |
| glumetinibrule | Haihe Biopharma | phase 3 | 8 |
| vilzemetkib | Sino Biopharmaceutical | phase 3 | 8 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| SHR-1826 | Jiangsu HengRui Medicine | phase 2 | 7 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06823245Advanced Non-small Cell Lung Cancer | 1 | Not yet recruiting | Hansoh Pharmaceutical Group | Jul 31, 2025 | 32 |
| NCT06110663Carcinoma, Non-Small-Cell Lung | 3 | Not yet recruiting | Hansoh Pharmaceutical Group | Dec 30, 2024 | 314 |
| NCT05430386Carcinoma, Non-Small-Cell Lung · China | 1 | UNKNOWN | Hansoh Pharmaceutical Group | Dec 31, 2023 | 174 |
| NCT04477057Solid Tumor · China | 1 | UNKNOWN | Hansoh Pharmaceutical Group | Dec 31, 2020 | 30 |
| NCT03243643Advanced Cancer · China | 1 | UNKNOWN | Hansoh Pharmaceutical Group | Jul 2019 | 80 |
| NCT02977364Carcinoma · China | 1 | UNKNOWN | Hansoh Pharmaceutical Group | Nov 2018 | 50 |
| NCT02759640Neoplasms · Australia | 1 | Completed | Jiangsu HengRui Medicine | Mar 2018 | 7 |
How it is read
Names in the registry
- “HS-10241”, 6 entries
- “HS-10241+ Almonertinib”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Neoplasms, 1 study
- Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.